Propranolol hydrochloride extended release - Cranford Pharmaceuticals

Drug Profile

Propranolol hydrochloride extended release - Cranford Pharmaceuticals

Alternative Names: Inderal XL; Sustained release propranolol hydrochloride - Cranford Pharmaceuticals

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Holmdel Pharmaceuticals
  • Developer Cranford Pharmaceuticals
  • Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 06 Jul 2017 Chemical structure information added
  • 24 Feb 2017 ANI Pharmaceuticals acquires Propranolol hydrochloride from Cranford pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top